• Shaanxi Micot Pharmaceutical Technology reported MT200605 preclinical and Phase I data accepted for an oral presentation at World Stroke Congress 2026.
• Presentation scheduled Oct. 21, 2026 in Seoul; findings have not yet been presented at the congress.
• Phase I studies in China and the US supported safety, tolerability, and pharmacokinetics in healthy volunteers.
• A Phase II acute ischemic stroke trial reached its primary endpoint with statistically significant, clinically meaningful outcomes; detailed results to be presented later.
• Update strengthens the program’s clinical momentum ahead of broader disclosure at future international conferences and journal publication.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Shaanxi Micot Pharmaceutical Technology Co. Ltd. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260810-12279295), on August 10, 2026, and is solely responsible for the information contained therein.